Eli Lilly and Company

Timothy Scott Kercher

Kevin Ronald Condroski

Andrew T Metcalf

Adedoyin David Abraham

Andrew Karl Dilger

Kaveri Balan Urkalan

Desta Doro Bume

Robert Alan Hazlitt

Shane Michael Walls

Andrew Terrance Metcalf

The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis(SADDAN), muenke syndrome or cancer.

FGFR3 inhibitor compounds

The present invention provides compounds of the formula: for use in the treatment of systemic sclerosis, fibrosis (e.g. pulmonary fibrosis), achondroplasia, thanatophoric dysplasia (e.g. type I), severe achondroplasia with developmental delay and acanthosis nigricans (SADDAN), muenke syndrome or cancer.

Growing community of inventors

Longmont, CO, United States of America

Timothy Scott Kercher